Expert report on immune checkpoint inhibitors for dMMR Colorectal Cancer

2 Views

07/07/23

Julien Taieb discusses abstracts presented at ESMO Congress 2022:
- LBA23: Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): the SAMCO-PRODIGE 54 randomised phase II trial
- LBA7: Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study

Produced by the European Society for Medical Oncology
http://oncologypro.esmo.org

This video was supported with an educational grant from Roche.
The study results covered, and the presenter of this expert video, have been selected exclusively by ESMO.